Transplant diagnostics market seen reaching $2.96 billion by 2030

The transplant diagnostics market is projected to grow from $2.07 billion in 2025 to $2.96 billion by 2030, driven by more organ transplants, better testing technology and wider use of AI and next-generation sequencing. North America held the largest share in 2025 as chronic disease rates and transplant activity continue to lift demand.

Why it matters: - Transplant diagnostics help match donor organs with recipients and lower the risk of rejection. - Faster and more precise testing can improve transplant success rates and patient outcomes. - Growing demand for transplants is pushing hospitals and labs to expand testing capacity.

What happened: - The transplant diagnostics market is projected to rise from $2.07 billion in 2025 to $2.25 billion in 2026. - The market is forecast to reach $2.96 billion by 2030, representing a 7.1% CAGR. - The report was released Sept. 1, 2026 by The Business Research Company. - The company published sample and full report links for the market study: Download a free sample and View the full report.

The details: - Growth in 2026 is tied to more organ transplant procedures, improved histocompatibility testing, higher rates of immunogenetic disorders, more transplant centers and government funding for organ donation. - Future growth is expected to come from AI and machine learning in diagnostic testing, broader use of next-generation sequencing, personalized immunotherapy, cloud-based diagnostics platforms and stronger public awareness of organ donation. - The report points to rapid histocompatibility testing, AI-assisted donor-recipient matching, molecular diagnostics, high-throughput screening and cloud-based transplant data management as key trends. - Transplant diagnostics cover tests that assess donor-recipient compatibility and health before transplantation. - Histocompatibility and immunogenetics are core focus areas for both organ transplantation and hematopoietic stem cell transplantation. - These tests are designed to improve matching and reduce organ rejection. - Rising chronic disease rates are a major demand driver because diabetes, heart disease and arthritis can lead to organ damage and transplant needs. - UK National Health Service data from June 2024 showed 3,615,330 people were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, up 18% from 3,065,825 the year before. - North America held the largest market share in 2025, supported by advanced healthcare infrastructure and high transplantation rates. - Western Europe ranked as the second-largest regional market. - The report also covers Asia-Pacific, South East Asia, Eastern Europe, South America, the Middle East and Africa. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, hotspot infographics, and updated graphics and tables.

Between the lines: - The market’s growth path reflects a shift from conventional compatibility testing toward data-heavy diagnostics. - AI, cloud platforms and sequencing tools suggest transplant labs are becoming more integrated with broader digital health systems. - Chronic disease growth increases the pool of patients who may eventually need transplants, which supports long-term testing demand.

What's next: - The market is expected to keep expanding as transplant volumes rise and diagnostic workflows become more automated. - Wider adoption of molecular and sequencing-based tools could reshape how centers evaluate donor-recipient matches. - Regional growth outside North America will likely depend on transplant infrastructure and organ donation awareness. - More information is available through the company’s LinkedIn page and social media channels.